A Phase 2 interventional study of AZD2693 and Placebo in Nonalcoholic Steatohepatitis, sponsored by AstraZeneca. Completed at 163 sites in 22 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca — none open to participants now, 1 under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · AstraZeneca.
Among the 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 2, and was the 16th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 1
First in 2011; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 48 across the 17 interventional studies, 881 across the 2 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
1 of the studies in Non-alcoholic Fatty Liver Disease by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele
Key Inclusion Criteria :
Participants are eligible to be included in the study only if all the following criteria apply:
Age
Participant must be 18 to 75 years of age (inclusive) at the time of signing the .
Type of Participant and Disease Characteristics
Participants with histological evidence of NASH based on central pathologist evaluation of a liver obtained up to 6 months before randomisation, or during screening, fulfilling both criteria:
<!-- -->
Key Exclusion Criteria :
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
Any of the following confirmed at the screening visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive AZD2693 dose 1
Drug: AZD2693
Participants will receive AZD2693 dose 2
Drug: AZD2693
Participants in this arm will receive placebo
Other: Placebo
AZD2693 solution SC once per month
Sodium chloride 0.9% solution SC once per month
Proportion of Participants Achieving NASH Resolution Without Worsening of Fibrosis Based on Histology After 52 Weeks of Treatment
To assess the effect of AZD2693 versus placebo on histological resolution of NASH in participants with non-cirrhotic NASH with fibrosis and PNPLA3 risk allele carriers after 52 weeks of treatment
Time frame: From baseline to week 54
Proportion of Participants With at Least One Stage of Liver Fibrosis Improvement With no Worsening of NASH Based on Biopsy After 52 Weeks of Treatment
To assess the effects of AZD2693 versus placebo on histological fibrosis improvement
Time frame: From baseline to week 54
Proportion of Participants With ≥ 2-point Improvement From Baseline in NAS Based on Biopsy After 52 Weeks of Treatment
To assess the effect of AZD2693 versus placebo on ≥ 2-point improvement in NAS
Time frame: From baseline to week 54
Proportion of Participants With Improvement in Fibrosis by at Least One Stage Based on Biopsy After 52 Weeks of Treatment
To assess the effect of AZD2693 versus placebo on improvement in fibrosis by at least one stage
Time frame: From baseline to week 54
Number of Participants With Abnormal Laboratory Test Results
Haematology, urinalysis, clinical chemistry and eGFR. Number of participants with abnormalities. A result of \>=++ for urinalysis (dipstick) results means ++ or worse (+++ or ++++).
Time frame: Baseline to 64 weeks
Number of Participants With Abnormal Vital Signs and ECG Results
Vital signs and electrocardiogram (ECG) assessments. Number of participants with abnormalities.
Time frame: Baseline to 64 weeks
| Milestone | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| Started | 73 | 69 | 74 |
| Completed | 67 | 61 | 69 |
| Not completed | 6 | 8 | 5 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 6 | 5 |
| Withdrew: Sae | 0 | 1 | 0 |
To assess the effect of AZD2693 versus placebo on histological resolution of NASH in participants with non-cirrhotic NASH with fibrosis and PNPLA3 risk allele carriers after 52 weeks of treatment
| Participants | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| Proportion of Participants Achieving NASH Resolution Without Worsening of Fibrosis Based on Histology After 52 Weeks of Treatment | 4 | 1 | 5 |
To assess the effects of AZD2693 versus placebo on histological fibrosis improvement
| Participants | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| Proportion of Participants With at Least One Stage of Liver Fibrosis Improvement With no Worsening of NASH Based on Biopsy After 52 Weeks of Treatment | 12 | 6 | 8 |
To assess the effect of AZD2693 versus placebo on ≥ 2-point improvement in NAS
| Participants | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| Proportion of Participants With ≥ 2-point Improvement From Baseline in NAS Based on Biopsy After 52 Weeks of Treatment | 22 | 12 | 23 |
To assess the effect of AZD2693 versus placebo on improvement in fibrosis by at least one stage
| Participants | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| Proportion of Participants With Improvement in Fibrosis by at Least One Stage Based on Biopsy After 52 Weeks of Treatment | 14 | 7 | 10 |
Haematology, urinalysis, clinical chemistry and eGFR. Number of participants with abnormalities. A result of \>=++ for urinalysis (dipstick) results means ++ or worse (+++ or ++++).
| Participants | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| ALT > 3ULN | 18 | 33 | 10 |
| ALP > 3ULN | 1 | 0 | 0 |
| AST > 3ULN | 11 | 18 | 11 |
| direct Bilirubin > ULN | 5 | 7 | 4 |
| Creatinine > ULN | 1 | 2 | 7 |
| B-platelet count > ULN | 9 | 5 | 9 |
| Blood >= ++ | 6 | 14 | 7 |
| Glucose >= ++ | 13 | 24 | 29 |
| Protein >= ++ | 6 | 4 | 4 |
| eGFR > 25% decrease | 1 | 3 | 10 |
Vital signs and electrocardiogram (ECG) assessments. Number of participants with abnormalities.
| Participants | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| Diastolic blood pressure from normal to high | 15 | 26 | 25 |
| Systolic blood pressure from normal to high | 29 | 30 | 28 |
| Pulse rate from normal to high | 2 | 3 | 7 |
| Temperature from normal to high | 12 | 10 | 18 |
| QTcF increase from baseline by more than 60 ms | 3 | 1 | 1 |
Collected over From baseline to 64 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD2693 25 mg | 0/73 (0%) | 7/73 (9.6%) | 49/73 (67.1%) |
| AZD2693 50 mg | 0/69 (0%) | 3/69 (4.3%) | 49/69 (71%) |
| Placebo | 0/74 (0%) | 7/74 (9.5%) | 53/74 (71.6%) |
| Event | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/73 | 1/69 | 1/74 |
| NeurosyphilisInfections and infestations | 0/73 | 1/69 | 0/74 |
| Myocardial ischaemiaCardiac disorders | 0/73 | 1/69 | 0/74 |
| Autoimmune hepatitisHepatobiliary disorders | 1/73 | 0/69 | 0/74 |
| Radius fractureInjury, poisoning and procedural complications | 1/73 | 0/69 | 1/74 |
| CostochondritisMusculoskeletal and connective tissue disorders | 1/73 | 0/69 | 0/74 |
| Cerebral infarctionNervous system disorders | 1/73 | 0/69 | 0/74 |
| HypotensionVascular disorders | 1/73 | 0/69 | 0/74 |
| Abdominal pain lowerGastrointestinal disorders | 1/73 | 0/69 | 0/74 |
| Dengue feverInfections and infestations | 1/73 | 0/69 | 0/74 |
| Event | AZD2693 25 mg | AZD2693 50 mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/73 | 10/69 | 11/74 |
| DiarrhoeaGastrointestinal disorders | 3/73 | 8/69 | 11/74 |
| Alanine aminotransferase increasedInvestigations | 3/73 | 9/69 | 1/74 |
| Urinary tract infectionInfections and infestations | 9/73 | 8/69 | 2/74 |
| Injection site erythemaGeneral disorders | 6/73 | 8/69 | 0/74 |
| Covid-19Infections and infestations | 4/73 | 8/69 | 3/74 |
| HeadacheNervous system disorders | 7/73 | 8/69 | 5/74 |
| Abdominal painGastrointestinal disorders | 0/73 | 8/69 | 2/74 |
| Upper respiratory tract infectionInfections and infestations | 7/73 | 7/69 | 4/74 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/73 | 1/69 | 7/74 |
| Age, Continuous(Years) | AZD2693 25 mg | AZD2693 50 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 53.7 ± 13.0 | 51.8 ± 13.3 | 53.7 ± 13.6 | 53.1 ± 13.3 |
| Sex: Female, Male(Participants) | AZD2693 25 mg | AZD2693 50 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 39 | 41 | 37 | 117 |
| Male | 34 | 28 | 37 | 99 |
| Race/Ethnicity, Customized(Participants) | AZD2693 25 mg | AZD2693 50 mg | Placebo | Total |
|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 5 | 0 | 2 | 7 |
| ASIAN | 19 | 19 | 27 | 65 |
| BLACK OR AFRICAN AMERICAN | 0 | 0 | 3 | 3 |
| MULTIPLE | 1 | 0 | 0 | 1 |
| NOT REPORTED | 2 | 4 | 2 | 8 |
| OTHER | 0 | 5 | 9 | 14 |
| WHITE | 46 | 41 | 31 | 118 |
| Region of Enrollment(Participants) | AZD2693 25 mg | AZD2693 50 mg | Placebo | Total |
|---|---|---|---|---|
| ARG | 1 | 3 | 1 | 5 |
| BRA | 3 | 3 | 8 | 14 |
| CHL | 1 | 6 | 0 | 7 |
| CHN | 2 | 4 | 4 | 10 |
| COL | 1 | 0 | 0 | 1 |
| DEU | 2 | 0 | 0 | 2 |
| ESP | 2 | 1 | 1 | 4 |
| HKG | 2 | 3 | 0 | 5 |
| ITA | 6 | 4 | 4 | 14 |
| JPN | 8 | 8 | 14 | 30 |
| KOR | 1 | 0 | 0 | 1 |
| MEX | 8 | 11 | 13 | 32 |
| MYS | 3 | 1 | 0 | 4 |
| PER | 2 | 0 | 1 | 3 |
| PHL | 1 | 1 | 3 | 5 |
| SGP | 1 | 1 | 1 | 3 |
| THA | 1 | 1 | 1 | 3 |
| TUR | 4 | 1 | 0 | 5 |
| TWN | 0 | 0 | 1 | 1 |
| USA | 24 | 21 | 21 | 66 |
| VNM | 0 | 0 | 1 | 1 |
Showing the first 100 of 163 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2023 to primary completion in Jul 2025, 27 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 27 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD2693
Non-alcoholic Fatty Liver Disease →